- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of September 9
The Center for Biosimilars® recaps the top stories for the week of September 9, 2019.
Transcript
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 9, 2019.
Number 5: Genentech has reached an agreement with JHL Biotech in a civil lawsuit related to trade secret theft. Under the agreement, JHL will have to destroy its biosimilar cell lines.
Number 4: The European Patent Office did not grant Alexion its request for 2 patents on Soliris.
Number 3: Celltrion has announced that its trastuzumab biosimilar, Herzuma, has received authorization from Health Canada.
Number 2: Patient organizations for those with inflammatory bowel disease are voicing concern about British Columbia’s plan to transition patients to biosimilars.
Number 1: A new report released Monday by UnitedHealth Group finds that administering specialty drugs outside of hospitals could save $4 billion each year.
Finally, last week, our e-newsletter asked what you think is the greatest challenge facing biosimilars in the United States.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan
June 17th 2025Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
